Bortezomib (BAN, INN and USAN. Originally codenamed PS-341; marketed as Velcade by Millennium Pharmaceuticals; Neomib by Getwell and Bortecad by Cadila Healthcare) is the first therapeutic proteasome inhibitor to be tested in humans. Proteasomes are cellular complexes that break down proteins. In some cancers, the proteins that normally kill cancer cells are broken down too quickly. Bortezomib interrupts this process and lets those proteins kill the cancer cells. It is approved in the U.S. for treating relapsed multiple myeloma and mantle cell lymphoma.
- ProName: Bortezomib, PS-341, LDP-341, MLM341
- CasNo:179324-69-7
- Molecular Formula: C19H25BN4O4
- Appearance: White to off-white Solid
- Application: Research use only. Not for human use.
- DeliveryTime: In Stock,Ship with in 48HRS.
- PackAge: Meet your requirments
- Port: Shanghai
- ProductionCapacity: 5 Kilogram/Month
- Purity: 99%
- Storage: Cool and dry place
- Transportation: FedEX, DHL, TNT, EMS
- LimitNum: 5 Milligram
No comments:
Post a Comment